|
1
|
Noto H, Goto A, Tsujimoto T, Osame K and
Noda M: Latest insights into the risk of cancer in diabetes. J
Diabetes Investig. 4:225–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sen S, He Y, Koya D and Kanasaki K: Cancer
biology in diabetes. J Diabetes Investig. 5:251–264. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Srokowski TP, Fang S, Hortobagyi GN and
Giordano SH: Impact of diabetes mellitus on complications and
outcomes of adjuvant chemotherapy in older patients with breast
cancer. J Clin Oncol. 27:2170–2176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chodick G, Heymann AD, Rosenmann L, Green
MS, Flash S, Porath A, Kokia E and Shalev V: Diabetes and risk of
incident cancer: A large population-based cohort study in Israel.
Cancer Causes Control. 21:879–887. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noto H, Tsujimoto T and Noda M:
Significantly increased risk of cancer in diabetes mellitus
patients: A meta-analysis of epidemiological evidence in Asians and
non-Asians. J Diabetes Investig. 2:24–33. 2012. View Article : Google Scholar
|
|
6
|
Suissa S and Azoulay L: Metformin and
cancer: Mounting evidence against an association. Diabetes Care.
37:1786–1788. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hemkens LG, Grouven U, Bender R, Günster
C, Gutschmidt S, Selke GW and Sawicki PT: Risk of malignancies in
patients with diabetes treated with human insulin or insulin
analogues: A cohort study. Diabetologia. 52:1732–1744. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mannucci E, Monami M, Balzi D, Cresci B,
Pala L, Melani C, Lamanna C, Bracali I, Bigiarini M, Barchielli A,
et al: Doses of insulin and its analogues and cancer occurrence in
insulin-treated type 2 diabetic patients. Diabetes Care.
33:1997–2003. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lind M, Fahlén M, Eliasson B and Odén A:
The relationship between the exposure time of insulin glargine and
risk of breast and prostate cancer: An observational study of the
time-dependent effects of antidiabetic treatments in patients with
diabetes. Prim Care Diabetes. 6:53–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weinstein D, Simon M, Yehezkel E, Laron Z
and Werner H: Insulin analogues display IGF1-like mitogenic and
anti-apoptotic activities in cultured cancer cells. Diabetes Metab
Res Rev. 25:41–49. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ljung R, Talbäck M, Haglund B, Jonasson
JM, Gudbjörnsdòttir S and Steineck G: Insulin glargine use and
short-term incidence of malignancies - a three-year
population-based observation. Acta Oncol. 50:685–693. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barclay AW, Petocz P, McMillan-Price J,
Flood VM, Prvan T, Mitchell P and Brand-Miller JC: Glycemic index,
glycemic load and chronic disease risk - a meta-analysis of
observational studies. Am J Clin Nutr. 87:627–637. 2008.PubMed/NCBI
|
|
13
|
Stocks T, Rapp K, Bjørge T, Manjer J,
Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S, et
al: Blood glucose and risk of incident and fatal cancer in the
metabolic syndrome and cancer project (me-can): Analysis of six
prospective cohorts. PLoS Med. 6:e10002012009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abe R and Yamagishi S: AGE-RAGE system and
carcinogenesis. Curr Pharm Des. 14:940–945. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Malek M, Aghili R, Emami Z and Khamseh M:
Risk of cancer in diabetes: The effect of metformin. ISRN
Endocrinol. 2013:6369272013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pulito C, Sanli T, Rana P, Muti P,
Blandino G and Strano S: Metformin: On ongoing journey across
diabetes, cancer therapy and prevention. Metabolites. 3:1051–1075.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Q, Celestino J, Schmandt R,
McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS,
Iglesias D, et al: Chemopreventive effects of metformin on
obesity-associated endometrial proliferation. Am J Obstet Gynecol.
209:e1–e24. 2013. View Article : Google Scholar
|
|
18
|
Del Barco S, Vazquez-Martin A, Cufí S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011.PubMed/NCBI
|
|
19
|
Dowling RJ, Goodwin PJ and Stambolic V:
Understanding the benefit of metformin use in cancer treatment. BMC
Med. 9:332011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Engelman JA and Cantley LC:
Chemoprevention meets glucose control. Cancer Prev Res (Phila).
3:1049–1052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fogarty S and Hardie DG: Development of
protein kinase activators: AMPK as a target in metabolic disorders
and cancer. Biochim Biophys Acta. 1804:581–591. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kubota T: Update in polycystic ovary
syndrome: New criteria of diagnosis and treatment in Japan. Reprod
Med Biol. 12:71–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Foretz M, Hébrard S, Leclerc J,
Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and
Viollet B: Metformin inhibits hepatic gluconeogenesis in mice
independently of the LKB1/AMPK pathway via a decrease in hepatic
energy state. J Clin Invest. 120:2355–2369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: Metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kalender A, Selvaraj A, Kim SY, Gulati P,
Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et
al: Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saeedi R, Parsons HL, Wambolt RB, Paulson
K, Sharma V, Dyck JR, Brownsey RW and Allard MF: Metabolic actions
of metformin in the heart can occur by AMPK-independent mechanisms.
Am J Physiol Heart Circ Physiol. 294:H2497–H2506. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Treins C, Murdaca J, Van Obberghen E and
Giorgetti-Peraldi S: AMPK activation inhibits the expression of
HIF-1alpha induced by insulin and IGF-1. Biochem Biophys Res
Commun. 342:1197–1202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J,
Lau S, Pollak MN and Bruchim I: n vitro metformin
anti-neoplastic activity in epithelial ovarian cancer. Gynecol
Oncol. 110:246–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alimova I, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest n
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Franciosi M, Lucisano G, Lapice E,
Strippoli G, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Home PD, Kahn SE, Jones NP, Noronha D,
Beck-Nielsen H and Viberti GADOPT Study Group and RECORD Steering
Committee: Experience of malignancies with oral glucose-lowering
drugs in the randomised controlled ADOPT (A Diabetes Outcome
Progression Trial) and RECORD (Rosiglitazone Evaluated for
Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes)
clinical trials. Diabetologia. 53:1838–1845. 2010.
|
|
35
|
Baur DM, Klotsche J, Hamnvik OP, Sievers
C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN and
Mantzoros CS: Type 2 diabetes mellitus and medications for type 2
diabetes mellitus are associated with risk for and mortality from
cancer in a German primary care cohort. Metabolism. 60:1363–1371.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dilokthornsakul P, Chaiyakunapruk N,
Termrungruanglert W, Pratoomsoot C, Saokeaw S and Sruamsiri R: The
effects of metformin on ovarian cancer: A systematic review. Int J
Gynecol Cancer. 23:1544–1551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Erices R, Bravo M, Gonzalez P, Oliva B,
Racordon D, Garrido M, Ibañez C, Kato S, Brañes J, Pizarro J, et
al: Metformin, at concentrations corresponding to the treatment of
diabetes, potentiates the cytotoxic effects of carboplatin in
cultures of ovarian cancer cells. Reprod Sci. 20:1433–1446. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity n
vivo. Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yasmeen A, Beauchamp MC, Piura E, Segal E,
Pollak M and Gotlieb WH: Induction of apoptosis by metformin in
epithelial ovarian cancer: Involvement of the BCL-2 family
proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim TH, Suh DH, Kim MK and Song YS:
Metformin against cancer stem cells through the modulation of
energy metabolism: Special considerations on ovarian cancer. Biomed
Res Int. 2014:1327022014.PubMed/NCBI
|
|
41
|
Xiao X, He Q, Lu C, Werle KD, Zhao RX,
Chen J, Davis BC, Cui R, Liang J and Xu ZX: Metformin impairs the
growth of liver kinase B1-intact cervical cancer cells. Gynecol
Oncol. 127:249–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nevadunsky NS, Van Arsdale A, Strickler
HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL and Einstein
MH: Metformin use and endometrial cancer survival. Gynecol Oncol.
132:236–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Siegal R, Ward E, Browley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fader AN, Arriba LN, Frasure HE and Von
Gruenigen VE: Endometrial cancer and obesity: Epidemiology,
biomarkers, prevention and survivorship. Gynecol Oncol.
114:121–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gunter M, Hoover D, Yu H,
Wassertheil-Smoller S, Manson J, Li J, Harris T, Rohan T, Xue X, Ho
G, et al: A prospective evaluation of insulin and insulin-like
growth factor-I as risk factors for endometrial cancer. Cancer
Epidemiol Biomarkers Prev. 17:921–929. 929. View Article : Google Scholar
|
|
46
|
Friberg E, Orsini N, Mantzoros CS and Wolk
A: Diabetes mellitus and risk of endometrial cancer: A
meta-analysis. Diabetologia. 50:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Currie CJ, Poole CD, Jenkins-Jones S, Gale
EA, Johnson JA and Morgan CL: Mortality after incident cancer in
people with and without type 2 diabetes: Impact of metformin on
survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ko E, Walter P, Jackson A, Clark L,
Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA
and Bae-Jump V: Metformin is associated with improved survival in
endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Becker C, Jick SS, Meier CR and Bodmer M:
Metformin and the risk of endometrial cancer: A case-control
analysis. Gynecol Oncol. 129:565–569. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation - implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tan B, Adya R, Chen J, Lehnert H, Saint
Cassia LJ and Randeva HS: Metformin treatment exerts antiinvasive
and antimetastatic effects in human endometrial carcinoma cells. J
Clin Endocrinol Metab. 96:808–816. 2012. View Article : Google Scholar
|
|
52
|
Hanna RK, Zhou C, Malloy KM, Sun L, Zhong
Y, Gehrig PA and Bae-Jump VL: Metformin potentiates the effects of
paclitaxel in endometrial cancer cells through inhibition of cell
proliferation and modulation of the mTOR pathway. Gynecol Oncol.
125:458–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
55
|
Shao R, Li X, Feng Y, Lin JF and Billig H:
Direct effects of metformin in the endometrium: A hypothetical
mechanism for the treatment of women with PCOS and endometrial
carcinoma. J Exp Clin Cancer Res. 33:412014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Takahashi A, Kimura F, Yamanaka A,
Takebayashi A, Kita N, Takahashi K and Murakami T: Metformin
impairs growth of endometrial cancer cells via cell cycle arrest
and concomitant autophagy and apoptosis. Cancer Cell Int.
14:532014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sarfstein R, Friedman Y, Attias-Geva Z,
Fishman A, Bruchim I and Werner H: Metformin downregulates the
insulin/IGF1 signaling pathway and inhibits different uterine
serous carcinoma (USC) cells proliferation and migration in
p53-dependent or -independent manners. PLoS One. 8:e615372013.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stevens RJ, Ali R, Bankhead CR, Bethel MA,
Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst J,
et al: Cancer outcomes and all-cause mortality in adults allocated
to metformin: Systematic review and collaborative meta-analysis of
randomised clinical trials. Diabetologia. 55:2593–2603. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang ZJ and Li S: The prognostic value of
metformin for cancer patients with concurrent diabetes: A
systematic review and meta-analysis. Diabetes Obes Metab.
16:707–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Costello M, Shrestha B, Eden J, Johnson NP
and Sjoblom P: Metformin versus oral contraceptive pill in
polycystic ovary syndrome: A cochrane review. Hum Reprod.
22:1200–1209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Costello M, Shrestha B, Eden J, Sjoblom P
and Johnson N: Insulin-sensitising drugs versus the combined oral
contraceptive pill for hirsutism, acne and risk of diabetes,
cardiovascular disease and endometrial cancer in polycystic ovary
syndrome. Cochrane Database Syst Rev. 24:CD0055522007.
|
